Harbour BioMed Announces 2023 Interim Results

[ad_1] CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2023 /PRNewswire/ — Harbour BioMed (“HBM”, or the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and…

Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director

[ad_1] CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 8, 2023 /PRNewswire/ — Harbour BioMed (the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of…

Harbour BioMed Reports Full Year 2022 Financial Results

[ad_1] CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 3, 2023 /PRNewswire/ — Harbour BioMed (“HBM” or the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization…